Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis

Osteoporosis International

Volumn 17, Issue 3, 2006, Pages 373-378

  Hwang, J S ^a   Tu, S T ^b   Yang, T S ^c   Chen, J F ^a   Wang, C J ^a   Tsai, K S ^d  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bone mineral density; Calcitonin; Osteoporosis; Teriparatide

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; NITROGEN; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; SALCATONIN; UREA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASIA; BONE DENSITY; BONE TURNOVER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEMUR NECK; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HIP; HUMAN; HYPERCALCEMIA; HYPERURICEMIA; LIVER DISEASE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEASUREMENT; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; OSSIFICATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMIC DISEASE; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VASODILATATION; VOMITING;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CHI-SQUARE DISTRIBUTION; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS, POSTMENOPAUSAL; TAIWAN; TERIPARATIDE;

EID: 33645215251     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-2002-5     Document Type: Article

References (27)

1. Charles W, Slemenda C, Johnston C Jr (1999) Epidemiology of osteoporosis. In: Lobo RA (ed) Treatment of the postmenopausal women: basic and clinical aspects. Lippincott Williams & Wilkins, Baltimore, pp 279-285
2. Yang TS, Chen YR, Chen YJ, et al (2004) Osteoporosis: prevalence in Taiwanese women. Osteoporos Int 15:345-347
3. Tsai KS, Tai TY (1997) Epidemiology of osteoporosis in Taiwan. Osteoporos Int 7:S96-S98
4. Riggs BL (1992) The problem of osteoporosis-its prevention and treatment. In: Riggs BL (ed) Prevention and treatment of osteoporosis. Hogrefe & Huber, Lewiston, pp 9-11
5. Cranney A, Guyatt G, Griffith L, et al (2002) Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578
6. Black DM, Cummings SR, Karpf DB, et al (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
7. Harris ST, Watts NB, Genant HK, et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282:1344-1352
8. Chesnut CH, Silverman S, Andriano K, et al. for the PROOF study group (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109:267-276
9. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282 637-645
10. Crandall C (2002) Parathyroid hormone for treatment of osteoporosis Arch Intern Med 162:2297-2309
11. Neer RM, Arnaud CD, Zanchetta JR, et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
12. Orwoll ES, Scheele WH, Paul S, et al (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
13. Kurland ES, Cosman F, McMahon DJ, et al (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076
14. Body JJ (2002) Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 30:75S-79S
15. Gruber HE, Ivey JL, Baylink DJ, et al (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295-303
16. Gennari C, Chierichetti SM, Bigazzi S, et al (1985) Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimes in post menopausal osteoporosis. Curr Ther Res 38:455-464
17. Mazzuoli GF, Passeri M, Gennari C, et al (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind study. Calcif Tissue Int 38:3-8
18. Genant HK, Wu CY, van Kujik C, et al (1993) Vertebral assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
19. Finkelstein JS (1996) Pharmacological mechanisms of therapeutics: parathyroid hormone. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology, 2nd edn, vol. 2. Academic, pp 993-1005
20. Hodsman AB, Fraher LJ, Watson PH, et al (1997) A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 82:620-628
21. Thamsborg G, Storm TL, Sykulski R, et al (1991) Effect of different doses of nasal salmon calcitonin on bone mass. Calcif Tissue Int 48:302-307
22. Overgaard K, Hansen MA, Jensen SB, et al (1992) Effect of calcitonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556-561
23. Reginster JY, Denis D, Albert A, et al (1987) Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (SSCT) by comparison with intramuscular (i.m.) or placebo injection in normal subjects. Bone Miner 2:133-140
24. Overgaard K, Agnusdei D, Hansen MA, et al (1991) Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 72:344-349
25. Rittmaster RS, Bolognese M, Ettinger MP, et al (2000) Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:2129-2134
26. Zanchetta JR, Bogado CE, Ferretti JL, et al (2003) Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539-543
27. Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604